

PRESENTERS FOR SYMPOSIUM 2:

Barriers to pharmacogenomic testing being incorporated into clinical practice

Dr Justin Rubio, Director, Genetics, Therapy Area Head, GlaxoSmithKline R&D



Justin completed a Ph.D. at the University of Melbourne in 1996, and conducted post-doctoral research at the Wellcome Trust Centre for Human Genetics (Oxford, UK) and Walter and Eliza Hall Institute (Melbourne), respectively. He established a Neurogenetics Laboratory at the Howard Florey Institute in 2004, and then took a position at GlaxoSmithKline (GSK) in the Genetics Division in 2009. Justin currently leads a programme of genetic and pharmacogenetic research that supports drug development across the GSK pipeline, from drug discovery through to clinical development and beyond, with a particular focus on the Neuroscience and Infectious Diseases therapy areas.

Professor Michael Murray, The University of Sydney



Michael Murray is with the Discipline of Pharmacology at The University of Sydney. After completing a PhD in Pharmaceutical Chemistry at the University of Sydney in 1982 and a postdoctoral period at Cornell University, he was appointed to the NHMRC Fellowship Scheme in 1987. In 1995 he received a D.Sc. from The University of Sydney. After 10 years as Professor of Pharmacogenomics he relocated to the Discipline of Pharmacology in 2013. Michael Murray is the author of over 180 publications since 1982 and has made 80 research presentations. He was an ASCEPT Councillor, and is an editorial board member of Toxicology and Applied Pharmacology and Xenobiotica.

Professor Robyn Ward, University of New South Wales



Prof Robyn Ward (MBBS, PhD, FRACP) is a medical oncologist and academic with over 20 years experience in lab-based, clinical, and health services research in cancer. She leads the Adult Cancer Program at the Lowy Cancer Research Centre, UNSW, is Clinical Associate Dean at the Prince of Wales Clinical School, and is specialist medical oncologist and Director of Cancer Services at Prince of Wales Hospital. She has extensive experience in health policy research, development and implementation at state and federal government level, is a long standing member of the Australian

Commonwealth's Pharmaceutical Benefits Advisory Committee and Chairs the Commonwealth's Medical Services Advisory Committee. Prof Ward's expertise in oncology and cancer biology has helped evaluate the effectiveness and cost effectiveness of subsidising drugs, and she has also helped develop policies regarding the best use of medicines in Australia. She was awarded the NSW Premier's Award for Individual Excellence and Achievement (2013), and was made a Member of the Order of Australia in 2013 for significant service to medical research and patient care in the field of oncology.

Professor Andrew Somogyi, University of Adelaide



Andrew Somogyi is Professor in Clinical and Experimental Pharmacology, Faculty of Health Sciences at the University of Adelaide. His major research interests are in examining interindividual variation in drug response through clinical pharmacokinetic, pharmacodynamic and clinical outcomes studies underpinned by pharmacogenomics through the therapeutic areas of pain management, addiction, transplantation and cancer. He has NHMRC funding for pharmacogenetic studies involving drugs for various conditions; he serves on several international Pharmacogenetic and Clinical Pharmacology journal editorial boards and has established a pharmacogenetics service at the Royal Adelaide Hospital. He is an honorary fellow of the Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists.

Australian and New Zealand College of Anaesthetists.